| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-06-09 | ALN-CC5 | complement-mediated diseases |
preclinical | Isis Pharmaceuticals (USA) | Immunological diseases |
| 2014-06-09 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | metastatic hormone-refractory prostate cancer | 2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-06-06 | Sivextro™ (tedizolid phosphate) | acute bacterial skin and skin structure infections (ABSSSI) complicated skin and soft tissue infections (cSSTI) |
3 | Cubist Pharmaceuticals (USA -MA) | Infectious diseases |
| 2014-06-05 | losmapimod | acute coronary syndrome |
3 | GSK (UK) | Cardiovascular diseases |
| 2014-06-05 | Orbactiv™ (oritavancin) | acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) | 3 | The Medicines Company (USA - NJ) | Infectious diseases |
| 2014-06-04 | AD04, AD02 | Alzheimer's disease |
2 | Affiris (Austria) | Neurodegenerative diseases |
| 2014-06-03 | Glybera® (alipogene tiparvovec) | lipoprotein lipase deficiency (LPLD) |
Uniqure (The Netherlands) | Rare diseases - Genetic diseases | |
| 2014-06-03 | riociguat | symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias |
2b | Bayer HealthCare (Germany) | Rare diseases - Cardiovascular diseases - Respiratory diseases |
| 2014-06-02 | Zykadia® (ceritinib) - LDK378 | anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) |
1 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-06-02 | CER-001 | Familial Primary Hypoalphalipoproteinemia (FPHA), Homozygous Familial Hypercholesterolemia (HoFH) | 2 | Cerenis Therapeutics (France) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2014-06-02 | ALKS 3831 (combination of a proprietary drug molecule, ALKS 33/samidorphan and olanzapine -Zyprexa®) | schizophrenia | 2 | Alkermes (Ireland) | Mental diseases |
| 2014-06-02 | talimogene laherparepvec | metastatic melanoma | 1 | Amgen (USA - CA) | Cancer - Oncology |
| 2014-06-02 | ruxolitinib | second-line metastatic pancreatic cancer |
2 | Incyte (USA) | Cancer - Oncology |
| 2014-06-02 | INCB24360 and ipilimumab | unresectable or metastatic melanoma |
1-2 | Incyte (USA) | Cancer - Oncology |
| 2014-06-01 | sonidegib - LDE225 | advanced basal cell carcinoma | 2 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-06-01 | evolocumab (AMG 145) | familial hypercholesterolemia | 2-3 | Amgen (USA -CA) | Genetic diseases - Cardiovascular diseases - Metabolic diseases |
| 2014-06-01 | lapatinib (Tykerb™/Tyverb™) and trastuzumab | HER2 positive early breast cancer |
3 | GSK (UK) | Cancer - Oncology |
| 2014-06-01 | Xtandi® (enzalutamide) | prostate cancer | 3 | Medivation (USA - CA) Astellas (Japan) | |
| 2014-05-31 | ALM AADx assay | ovarian cancer |
Almac Group (UK) | Cancer - Oncology | |
| 2014-05-31 | MPDL3280A (atezolizumab) | metastatic bladder cancer |
1 | Roche (Switzerland) | Cancer - Oncology |
